Stock ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
8.47 USD -1.40% Intraday chart for Arcutis Biotherapeutics, Inc. -6.92% +162.23%
Apr. 10 Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes CI
Mar. 18 Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index CI

Business Summary

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

Number of employees: 296

Sales per Business

USD in Million2022Weight2023Weight Delta
Dermatological Treatments
100.0 %
4 100.0 % 60 100.0 % +1,517.09%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
4 100.0 % 60 100.0 % +1,517.09%

Managers

Managers TitleAgeSince
Todd Watanabe CEO
 Chief Executive Officer 55 15-12-31
Rajvir Madan CTO
 Chief Tech/Sci/R&D Officer - 21-05-31
Jay Ramsinghani COO
 Chief Operating Officer - 20-05-26
Patrick Burnett CTO
 Chief Tech/Sci/R&D Officer 52 20-07-31
Courtney Barton CMP
 Compliance Officer 41 21-02-17
Howard Welgus BRD
 Director/Board Member 72 15-12-31
Jessica Robison AUD
 Comptroller/Controller/Auditor - 18-12-31
Bruce Binkowitz PRN
 Corporate Officer/Principal - 21-08-22
Matthew Moore PRN
 Corporate Officer/Principal - 21-01-10
Charlotte Merritt LAW
 General Counsel 61 16-12-31

Members of the board

Members of the board TitleAgeSince
Patrick Heron CHM
 Chairman 53 16-03-31
Bhaskar Chaudhuri FOU
 Founder 69 16-05-31
Keith Leonard BRD
 Director/Board Member 62 21-09-01
Halley Gilbert BRD
 Director/Board Member 54 20-04-30
Howard Welgus BRD
 Director/Board Member 72 15-12-31
Terrie Curran BRD
 Director/Board Member 55 20-11-01
Todd Watanabe CEO
 Chief Executive Officer 55 15-12-31
Sue-Jean Lin BRD
 Director/Board Member 65 21-06-08
Neha Krishnamohan BRD
 Director/Board Member 37 22-09-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 114,945,238 112,076,444 ( 97.50 %) 0 97.50 %

Shareholders

NameEquities%Valuation
Jennison Associates LLC
10.77 %
12,128,533 10.77 % 120 M $
Jennison Associates LLC
8.051 %
9,066,082 8.051 % 90 M $
Frazier Management LLC
7.802 %
8,785,284 7.802 % 87 M $
Suvretta Capital Management LLC
7.525 %
8,473,101 7.525 % 84 M $
Rubric Capital Management LP
5.901 %
6,644,530 5.901 % 66 M $
POLAR CAPITAL HOLDINGS PLC
5.593 %
6,297,688 5.593 % 62 M $
Morgan Stanley Investment Management, Inc.
5.402 %
6,083,072 5.402 % 60 M $
BlackRock Advisors LLC
5.036 %
5,671,214 5.036 % 56 M $
Vanguard Fiduciary Trust Co.
4.348 %
4,896,513 4.348 % 49 M $
Point72 Asset Management LP
4.323 %
4,867,706 4.323 % 48 M $

Company contact information

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road Suite 300

91361, Westlake Village

+

http://www.arcutis.com
address Arcutis Biotherapeutics, Inc.(ARQT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Arcutis Biotherapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.47 USD
Average target price
18 USD
Spread / Average Target
+112.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ARCUTIS BIOTHERAPEUTICS, INC. Stock Arcutis Biotherapeutics, Inc.
+162.23% 974M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ARQT Stock
  4. Company Arcutis Biotherapeutics, Inc.